Multiple Sclerosis (MS) is an autoimmune disease-causing demethylation of neurons. Researchers from the Karolinska Institute and the University of Zurich have shown that B lymphocytes are the driving force behind the demethylating action of T cells, causing MS. This finding published in Cell can be a landmark in justifying the clinical use of rituximab and ocrelizumab in MS. Multiple Sclerosis affects around 2.5 million people worldwide, with its prevalence in India being 8.35:100,000.
Until recently, MS research was mainly focused on a type of immune cells called T cells. Research showed that it was not only T cells, but B cells (B lymphocyte) as well which played a role in the development of the disease by activating of T cells. Further analysis of B lymphocyte activated T cells showed them to be identical to those which occurred in the brain of MS patients during a flare-up process.…
